DOCSLIB.ORG

Exome Sequencing Reanalysis on a Manitoba Cohort

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Harnessing the Power of Old Data: Exome Sequencing Reanalysis on a Manitoba Cohort by Taryn Bryn Tristan Athey A Thesis submitted to the Faculty of Graduate Studies of The University of Manitoba in partial fulfilment of the requirements of the degree of MASTER OF SCIENCE Department of Biochemistry and Medical Genetics Genetic Counselling Program Max Rady College of Medicine Rady Faculty of Health Sciences University of Manitoba Winnipeg, Manitoba, Canada Copyright ©2020 by Taryn Athey ABSTRACT Rare disorders are thought to affect 1 in 12 Canadians, yet more than 50% of these patients currently do not have a diagnosis. Undiagnosed and misdiagnosed patients with rare disorders cause a significant burden to the healthcare system and the uncertainty often greatly affects their quality of life. Exome sequencing (ES) is an unbiased genetic testing method that sequences most of the known coding regions in the genome. ES is used when targeted methods have failed to provide a diagnosis and has been found to lead to a definitive diagnosis in 25-50% of cases, depending on the criteria used for case selection. Clinical ES is limited by the bioinformatics method used to call variants, the interpretation of those variants, and the knowledge of gene-disease associations at the time of interpretation. Therefore, it is not surprising that systematic reanalysis of ES data at regular intervals has been shown to provide a diagnosis in an additional 10-15% of cases. ES reanalysis is not routinely done for Manitoba patients; for this reason, we have developed a pilot project to reanalyze the ES data for patients who previously had non-diagnostic ES. We recruited 33 participants from 25 families who have received ES that failed to provide a definitive genetic diagnosis. The raw ES data for each participant was collected from the sequencing laboratories and variants were called using the bcbio-nextgen bioinformatics pipeline. Variants were annotated using the Ensembl Variant Effect Predictor. Custom filters were used to prioritize variants for review and pathogenicity of variants was assessed using the American College of Medical Genetics guidelines. We found candidate variants in 14 (56%) of the families analyzed, including 3 strong candidate variants and 6 variants in novel genes that have not previously been associated with disease. This study suggests that reanalyzing already generated ES data is an efficient way to increase genetic diagnoses for I patients in Manitoba. As well, analysis of variants in genes with unknown function may lead to future gene discovery projects, adding to our overall knowledge of human genetics. II ACKNOWLEDGMENTS Thank you to my thesis supervisor, Dr. Patrick Frosk, for his guidance throughout the project, for sharing his vast knowledge of medical genetics, for going through endless lists of gene candidates with me, and for teaching me that negative is just a state of mind. Thank you to my thesis committee, Claudia Carriles, Taila Hartley, and Dr. Pingzhao Hu, for all of your individual insights and guidance. Thank you to my program director, Jessica Hartley, for keeping me organized and for our office chats. This work could not have been completed without the help of Shirley Harvey who contacted participants for their consent, found all of the charts I had to review, and always knew the answer to my questions. I also want to extend my gratitude to the Care4Rare team: Grace Ediae, Magda Price, and Michelle Vandeloo, for assisting with Care4Rare ethics procedures and data accession. Thank you to Matt Osmond for his matchmaking expertise and guidance during exome rounds. A big thank you to the inaugural class, Angela Krutish, Ashleigh Hansen, and Rachelle Dinchong, for leading the charge and for showing me that success is possible. Thank you to my classmates, Emily Bonnell and Selina Casalino, for the love, support, commiseration, and good times throughout the program. Best of luck to the remaining genetic counselling students, Natasha Osawa, Cassie McDonald, and Dorothy Michalski, I’m so glad to have gotten to know you this past year. I would also like to extend my appreciation to the many supervisors I had throughout this program. I am grateful to my husband, Charlie Keown-Stoneman, for spending more time on airplanes these past two years than the rest of his life combined, and for always answering the phone when I was having a tough day. Thank you to the rest of my friends and family for their endless love and support. III I would like to acknowledge the families who were involved in this study. Living through a diagnostic odyssey cannot be easy, and I feel privileged to have had the opportunity to assist them in finding diagnoses. I received funding from the University of Manitoba Graduate Fellowship (Department of Biochemistry and Medical Genetics). IV TABLE OF CONTENTS ABSTRACT ....................................................................................................................................................... I ACKNOWLEDGMENTS .................................................................................................................................. III TABLE OF CONTENTS ..................................................................................................................................... V LIST OF TABLES ............................................................................................................................................. IX LIST OF FIGURES ............................................................................................................................................ X LIST OF ABBREVIATIONS .............................................................................................................................. XI CHAPTER 1: BACKGROUND AND REVIEW OF THE LITERATURE .................................................................... 1 1.1. Rare Disease ....................................................................................................................................... 1 1.2. Traditional Methods of Diagnosis ...................................................................................................... 2 1.3. Exome Sequencing ............................................................................................................................. 3 1.3.1. Criteria for Testing ...................................................................................................................... 3 1.3.2. Factors that Affect Diagnostic Rates ........................................................................................... 4 1.3.3. Beyond Single Nucleotide Causes of Disease .............................................................................. 6 1.3.4. Secondary Findings ..................................................................................................................... 8 1.3.5. When Exome Sequencing Cannot Find a Diagnosis .................................................................... 9 1.4. Exome Sequencing Reanalysis ........................................................................................................... 9 1.4.1. New Disease-Gene Associations ................................................................................................. 9 1.4.2. Variant Interpretation ............................................................................................................... 10 1.4.3. Trio Exome Sequencing as a Way to Increase Diagnoses ......................................................... 11 1.4.4. Bioinformatic Considerations .................................................................................................... 12 1.4.5. When to Reanalyse ................................................................................................................... 13 1.5. Clinical Analysis Versus Research Analysis ....................................................................................... 13 1.6. Potential Benefits of Genetic Diagnosis ........................................................................................... 14 1.7. Manitoba Population ....................................................................................................................... 17 1.8. Thesis Rationale ............................................................................................................................... 18 CHAPTER 2: METHODS ................................................................................................................................ 20 2.1. Ethics Approval ................................................................................................................................ 20 2.2. Participant Recruitment ................................................................................................................... 20 2.3. Chart Review and Phenotype Abstraction ....................................................................................... 22 2.4. Data Transfer ................................................................................................................................... 23 V 2.5. Bioinformatics Pipeline .................................................................................................................... 24 2.6. Variant Filtration .............................................................................................................................. 24 2.6.1. Filter 1: New Disease-Gene Associations and Previously Miscalled Variants
Recommended publications
  • Analysis of Gene Expression Data for Gene Ontology

    Analysis of Gene Expression Data for Gene Ontology

    ANALYSIS OF GENE EXPRESSION DATA FOR GENE ONTOLOGY BASED PROTEIN FUNCTION PREDICTION A Thesis Presented to The Graduate Faculty of The University of Akron In Partial Fulfillment of the Requirements for the Degree Master of Science Robert Daniel Macholan May 2011 ANALYSIS OF GENE EXPRESSION DATA FOR GENE ONTOLOGY BASED PROTEIN FUNCTION PREDICTION Robert Daniel Macholan Thesis Approved: Accepted: _______________________________ _______________________________ Advisor Department Chair Dr. Zhong-Hui Duan Dr. Chien-Chung Chan _______________________________ _______________________________ Committee Member Dean of the College Dr. Chien-Chung Chan Dr. Chand K. Midha _______________________________ _______________________________ Committee Member Dean of the Graduate School Dr. Yingcai Xiao Dr. George R. Newkome _______________________________ Date ii ABSTRACT A tremendous increase in genomic data has encouraged biologists to turn to bioinformatics in order to assist in its interpretation and processing. One of the present challenges that need to be overcome in order to understand this data more completely is the development of a reliable method to accurately predict the function of a protein from its genomic information. This study focuses on developing an effective algorithm for protein function prediction. The algorithm is based on proteins that have similar expression patterns. The similarity of the expression data is determined using a novel measure, the slope matrix. The slope matrix introduces a normalized method for the comparison of expression levels throughout a proteome. The algorithm is tested using real microarray gene expression data. Their functions are characterized using gene ontology annotations. The results of the case study indicate the protein function prediction algorithm developed is comparable to the prediction algorithms that are based on the annotations of homologous proteins.
  • (TEX) Genes: a Review Focused on Spermatogenesis and Male Fertility

    (TEX) Genes: a Review Focused on Spermatogenesis and Male Fertility

    Bellil et al. Basic and Clinical Andrology (2021) 31:9 https://doi.org/10.1186/s12610-021-00127-7 REVIEW ARTICLE Open Access Human testis-expressed (TEX) genes: a review focused on spermatogenesis and male fertility Hela Bellil1, Farah Ghieh2,3, Emeline Hermel2,3, Béatrice Mandon-Pepin2,3 and François Vialard1,2,3* Abstract Spermatogenesis is a complex process regulated by a multitude of genes. The identification and characterization of male-germ-cell-specific genes is crucial to understanding the mechanisms through which the cells develop. The term “TEX gene” was coined by Wang et al. (Nat Genet. 2001; 27: 422–6) after they used cDNA suppression subtractive hybridization (SSH) to identify new transcripts that were present only in purified mouse spermatogonia. TEX (Testis expressed) orthologues have been found in other vertebrates (mammals, birds, and reptiles), invertebrates, and yeasts. To date, 69 TEX genes have been described in different species and different tissues. To evaluate the expression of each TEX/tex gene, we compiled data from 7 different RNA-Seq mRNA databases in humans, and 4 in the mouse according to the expression atlas database. Various studies have highlighted a role for many of these genes in spermatogenesis. Here, we review current knowledge on the TEX genes and their roles in spermatogenesis and fertilization in humans and, comparatively, in other species (notably the mouse). As expected, TEX genes appear to have a major role in reproduction in general and in spermatogenesis in humans but also in all mammals such as the mouse. Most of them are expressed specifically or predominantly in the testis.
  • NICU Gene List Generator.Xlsx

    NICU Gene List Generator.Xlsx

    Neonatal Crisis Sequencing Panel Gene List Genes: A2ML1 - B3GLCT A2ML1 ADAMTS9 ALG1 ARHGEF15 AAAS ADAMTSL2 ALG11 ARHGEF9 AARS1 ADAR ALG12 ARID1A AARS2 ADARB1 ALG13 ARID1B ABAT ADCY6 ALG14 ARID2 ABCA12 ADD3 ALG2 ARL13B ABCA3 ADGRG1 ALG3 ARL6 ABCA4 ADGRV1 ALG6 ARMC9 ABCB11 ADK ALG8 ARPC1B ABCB4 ADNP ALG9 ARSA ABCC6 ADPRS ALK ARSL ABCC8 ADSL ALMS1 ARX ABCC9 AEBP1 ALOX12B ASAH1 ABCD1 AFF3 ALOXE3 ASCC1 ABCD3 AFF4 ALPK3 ASH1L ABCD4 AFG3L2 ALPL ASL ABHD5 AGA ALS2 ASNS ACAD8 AGK ALX3 ASPA ACAD9 AGL ALX4 ASPM ACADM AGPS AMELX ASS1 ACADS AGRN AMER1 ASXL1 ACADSB AGT AMH ASXL3 ACADVL AGTPBP1 AMHR2 ATAD1 ACAN AGTR1 AMN ATL1 ACAT1 AGXT AMPD2 ATM ACE AHCY AMT ATP1A1 ACO2 AHDC1 ANK1 ATP1A2 ACOX1 AHI1 ANK2 ATP1A3 ACP5 AIFM1 ANKH ATP2A1 ACSF3 AIMP1 ANKLE2 ATP5F1A ACTA1 AIMP2 ANKRD11 ATP5F1D ACTA2 AIRE ANKRD26 ATP5F1E ACTB AKAP9 ANTXR2 ATP6V0A2 ACTC1 AKR1D1 AP1S2 ATP6V1B1 ACTG1 AKT2 AP2S1 ATP7A ACTG2 AKT3 AP3B1 ATP8A2 ACTL6B ALAS2 AP3B2 ATP8B1 ACTN1 ALB AP4B1 ATPAF2 ACTN2 ALDH18A1 AP4M1 ATR ACTN4 ALDH1A3 AP4S1 ATRX ACVR1 ALDH3A2 APC AUH ACVRL1 ALDH4A1 APTX AVPR2 ACY1 ALDH5A1 AR B3GALNT2 ADA ALDH6A1 ARFGEF2 B3GALT6 ADAMTS13 ALDH7A1 ARG1 B3GAT3 ADAMTS2 ALDOB ARHGAP31 B3GLCT Updated: 03/15/2021; v.3.6 1 Neonatal Crisis Sequencing Panel Gene List Genes: B4GALT1 - COL11A2 B4GALT1 C1QBP CD3G CHKB B4GALT7 C3 CD40LG CHMP1A B4GAT1 CA2 CD59 CHRNA1 B9D1 CA5A CD70 CHRNB1 B9D2 CACNA1A CD96 CHRND BAAT CACNA1C CDAN1 CHRNE BBIP1 CACNA1D CDC42 CHRNG BBS1 CACNA1E CDH1 CHST14 BBS10 CACNA1F CDH2 CHST3 BBS12 CACNA1G CDK10 CHUK BBS2 CACNA2D2 CDK13 CILK1 BBS4 CACNB2 CDK5RAP2
  • Constructing and Analyzing Biological Interaction Networks for Knowledge Discovery

    Constructing and Analyzing Biological Interaction Networks for Knowledge Discovery

    Constructing and Analyzing Biological Interaction Networks for Knowledge Discovery Dissertation Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Duygu Ucar Graduate Program in Computer Science and Engineering The Ohio State University 2009 Dissertation Committee: Srinivasan Parthasarathy, Advisor Yusu Wang Umit Catalyurek c Copyright by Duygu Ucar 2009 ABSTRACT Many biological datasets can be effectively modeled as interaction networks where nodes represent biological entities of interest such as proteins, genes, or complexes and edges mimic associations among them. The study of these biological network structures can provide insight into many biological questions including the functional characterization of genes and gene products, the characterization of DNA-protein bindings, and the under- standing of regulatory mechanisms. Therefore, the task of constructing biological interac- tion networks from raw data sets and exploiting information from these networks is critical, but is also fraught with challenges. First, the network structure is not always known in a priori; the structure should be inferred from raw and heterogeneous biological data sources. Second, biological networks are noisy (containing unreliable interactions) and incomplete (missing real interactions) which makes the task of extracting useful information difficult. Third, typically these networks have non-trivial topological properties (e.g., uneven degree distribution, small world) that limit the effectiveness of traditional knowledge discovery al- gorithms. Fourth, these networks are usually dynamic and investigation of their dynamics is essential to understand the underlying biological system. In this thesis, we address these issues by presenting a set of computational techniques that we developed to construct and analyze three specific types of biological interaction networks: protein-protein interaction networks, gene co-expression networks, and regulatory networks.
  • Dock3 Stimulates Axonal Outgrowth Via GSK-3ß-Mediated Microtubule

    Dock3 Stimulates Axonal Outgrowth Via GSK-3ß-Mediated Microtubule

    264 • The Journal of Neuroscience, January 4, 2012 • 32(1):264–274 Development/Plasticity/Repair Dock3 Stimulates Axonal Outgrowth via GSK-3␤-Mediated Microtubule Assembly Kazuhiko Namekata, Chikako Harada, Xiaoli Guo, Atsuko Kimura, Daiji Kittaka, Hayaki Watanabe, and Takayuki Harada Visual Research Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan Dock3, a new member of the guanine nucleotide exchange factors, causes cellular morphological changes by activating the small GTPase Rac1. Overexpression of Dock3 in neural cells promotes axonal outgrowth downstream of brain-derived neurotrophic factor (BDNF) signaling. We previously showed that Dock3 forms a complex with Fyn and WASP (Wiskott–Aldrich syndrome protein) family verprolin- homologous (WAVE) proteins at the plasma membrane, and subsequent Rac1 activation promotes actin polymerization. Here we show that Dock3 binds to and inactivates glycogen synthase kinase-3␤ (GSK-3␤) at the plasma membrane, thereby increasing the nonphos- phorylated active form of collapsin response mediator protein-2 (CRMP-2), which promotes axon branching and microtubule assembly. Exogenously applied BDNF induced the phosphorylation of GSK-3␤ and dephosphorylation of CRMP-2 in hippocampal neurons. More- over, increased phosphorylation of GSK-3␤ was detected in the regenerating axons of transgenic mice overexpressing Dock3 after optic nerve injury. These results suggest that Dock3 plays important roles downstream of BDNF signaling in the CNS, where it regulates cell polarity and promotes axonal outgrowth by stimulating dual pathways: actin polymerization and microtubule assembly. Introduction We recently detected a common active center of Dock1ϳ4 within The Rho-GTPases, including Rac1, Cdc42, and RhoA, are best the DHR-2 domain and reported that the DHR-1 domain is nec- known for their roles in regulating the actin cytoskeleton and are essary for the direct binding between Dock1ϳ4 and WAVE1ϳ3 implicated in a broad spectrum of biological functions, such as (Namekata et al., 2010).
  • Making Ribosomes: Biochemical and Structural Studies of Early Ribosome Biogenesis in Yeast Malik Chaker-Margot

    Making Ribosomes: Biochemical and Structural Studies of Early Ribosome Biogenesis in Yeast Malik Chaker-Margot

    Rockefeller University Digital Commons @ RU Student Theses and Dissertations 2018 Making Ribosomes: Biochemical and Structural Studies of Early Ribosome Biogenesis in Yeast Malik Chaker-Margot Follow this and additional works at: https://digitalcommons.rockefeller.edu/ student_theses_and_dissertations Part of the Life Sciences Commons Recommended Citation Chaker-Margot, Malik, "Making Ribosomes: Biochemical and Structural Studies of Early Ribosome Biogenesis in Yeast" (2018). Student Theses and Dissertations. 472. https://digitalcommons.rockefeller.edu/student_theses_and_dissertations/472 This Thesis is brought to you for free and open access by Digital Commons @ RU. It has been accepted for inclusion in Student Theses and Dissertations by an authorized administrator of Digital Commons @ RU. For more information, please contact [email protected]. MAKING RIBOSOMES: BIOCHEMICAL AND STRUCTURAL STUDIES OF EARLY RIBOSOME BIOGENESIS IN YEAST A Thesis Presented to the Faculty of The Rockefeller University in Partial Fulfillment of the Requirements for the degree of Doctor of Philosophy by Malik Chaker-Margot June 2018 © Copyright by Malik Chaker-Margot 2018 MAKING RIBOSOMES: BIOCHEMICAL AND STRUCTURAL STUDIES OF EARLY RIBOSOME BIOGENESIS IN YEAST Malik Chaker-Margot, Ph.D. The Rockefeller University 2018 The ribosome is a complex macromolecule responsible for the synthesis of all proteins in the cell. In yeast, it is made of four ribosomal RNAs and 79 proteins, asymmetrically divided in a small and large subunit. In a growing yeast cell, more than 2000 ribosomes are assembled every minute. The ribosome is assembled through a highly complex process involving more than 200 trans-acting factors. Ribosome assembly begins in the nucleolus where RNA polymerase I transcribes a long polycistronic RNA, the 35S pre- ribosomal RNA which contains the sequences for three of the four ribosomal RNAs, as well as spacer sequences which are transcribed and removed during assembly.
  • Pathogenic Variants in the DEAH-Box RNA Helicase DHX37 Are a Frequent Cause of 46,XY Gonadal Dysgenesis and 46,XY Testicular Regression Syndrome

    Pathogenic Variants in the DEAH-Box RNA Helicase DHX37 Are a Frequent Cause of 46,XY Gonadal Dysgenesis and 46,XY Testicular Regression Syndrome

    ARTICLE © American College of Medical Genetics and Genomics Pathogenic variants in the DEAH-box RNA helicase DHX37 are a frequent cause of 46,XY gonadal dysgenesis and 46,XY testicular regression syndrome Ken McElreavey, PhD 1, Anne Jorgensen, PhD 2, Caroline Eozenou, PhD1, Tiphanie Merel, MSc1, Joelle Bignon-Topalovic, BSc1, Daisylyn Senna Tan, BSc3, Denis Houzelstein, PhD 1, Federica Buonocore, PhD 4, Nick Warr, PhD 5, Raissa G. G. Kay, PhD5, Matthieu Peycelon, MD, PhD 6,7,8, Jean-Pierre Siffroi, MD, PhD6, Inas Mazen, MD9, John C. Achermann, MD, PhD 4, Yuliya Shcherbak, MD10, Juliane Leger, MD, PhD11, Agnes Sallai, MD 12, Jean-Claude Carel, MD, PhD 11, Laetitia Martinerie, MD, PhD11, Romain Le Ru, MD13, Gerard S. Conway, MD, PhD14, Brigitte Mignot, MD15, Lionel Van Maldergem, MD, PhD 16, Rita Bertalan, MD, PhD17, Evgenia Globa, MD, PhD 18, Raja Brauner, MD, PhD19, Ralf Jauch, PhD 3, Serge Nef, PhD 20, Andy Greenfield, PhD5 and Anu Bashamboo, PhD1 Purpose: XY individuals with disorders/differences of sex devel- specifically associated with gonadal dysgenesis and TRS. opment (DSD) are characterized by reduced androgenization Consistent with a role in early testis development, DHX37 is caused, in some children, by gonadal dysgenesis or testis regression expressed specifically in somatic cells of the developing human during fetal development. The genetic etiology for most patients and mouse testis. with 46,XY gonadal dysgenesis and for all patients with testicular Conclusion: DHX37 pathogenic variants are a new cause of an regression syndrome (TRS) is unknown. autosomal dominant form of 46,XY DSD, including gonadal Methods: We performed exome and/or Sanger sequencing in 145 dysgenesis and TRS, showing that these conditions are part of a individuals with 46,XY DSD of unknown etiology including clinical spectrum.
  • Identification of Potential Key Genes and Pathway Linked with Sporadic Creutzfeldt-Jakob Disease Based on Integrated Bioinformatics Analyses

    Identification of Potential Key Genes and Pathway Linked with Sporadic Creutzfeldt-Jakob Disease Based on Integrated Bioinformatics Analyses

    medRxiv preprint doi: https://doi.org/10.1101/2020.12.21.20248688; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Identification of potential key genes and pathway linked with sporadic Creutzfeldt-Jakob disease based on integrated bioinformatics analyses Basavaraj Vastrad1, Chanabasayya Vastrad*2 , Iranna Kotturshetti 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. 3. Department of Ayurveda, Rajiv Gandhi Education Society`s Ayurvedic Medical College, Ron, Karnataka 562209, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.12.21.20248688; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Abstract Sporadic Creutzfeldt-Jakob disease (sCJD) is neurodegenerative disease also called prion disease linked with poor prognosis. The aim of the current study was to illuminate the underlying molecular mechanisms of sCJD. The mRNA microarray dataset GSE124571 was downloaded from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) were screened.
  • Lfp Cv May 2021 1

    Lfp Cv May 2021 1

    Curriculum Vitae Luis F. Parada, Ph.D. [email protected] 1275 York Avenue, Box 558 New York, NY 10065 T 646-888-3781 www.mskcc.org Education & positions held 1979 B.S., Molecular Biology (with Honors), University of Wisconsin-Madison, Wisconsin 1985 Ph.D., Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 1985 - 1987 Postdoctoral Fellow, Unité de Génetique Cellulaire, Pasteur Institute, Paris, France 1988 - 1994 Head, Molecular Embryology Group & Molecular Embryology Section (with tenure), Mammalian Genetics Laboratory, ABL-Basic Research Program, NCI-Frederick Cancer Research and Development Center, Frederick, Maryland 1994 - 2006 Director, Center for Developmental Biology and Professor of Cell Biology University of Texas Southwestern Medical Center, Dallas, TX 1995 - 2015 Diana and Richard C. Strauss Distinguished Chair in Developmental Biology 1997 - 2015 Director, Kent Waldrep Center for Basic Research on Nerve Growth and Regeneration 1998 - 2015 Southwestern Ball Distinguished Chair in Basic Neuroscience Research 2003 - American Cancer Society Research Professor 2006 - 2015 Chairman, Department of Developmental Biology, University of Texas Southwestern Medical School 2015- Director, Brain Tumor Center & Member Cancer Biology and Genetics Program, SKI & MSKCC 2015- Albert C. Foster Chair, SKI & MSKCC 2015- Attending Neuroscientist, Departments of Neurology and Neurosurgery, MSKCC Luis F. Parada Page 2 of 28 Honors 2018 EACR Keynote Lecture. The 4th Brain Tumours 2018: From Biology to Therapy Conference. Warsaw, Poland. 2018 Keynote Lecture CRUK Brain Tumour Conference 2018. London 2016 - 2023 NCI Outstanding Investigator Award (R35) 2015 Distinguished Lectureship in Cancer Biology, MD Anderson 2014 The Maestro Award – Dallas, TX 2014 The Herman Vanden Berghe Lectures – University of Leuven, Belgium 2013 Blaffer Lecture – M.D.
  • Whole Exome Sequencing in Families at High Risk for Hodgkin Lymphoma: Identification of a Predisposing Mutation in the KDR Gene

    Whole Exome Sequencing in Families at High Risk for Hodgkin Lymphoma: Identification of a Predisposing Mutation in the KDR Gene

    Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene Melissa Rotunno, 1 Mary L. McMaster, 1 Joseph Boland, 2 Sara Bass, 2 Xijun Zhang, 2 Laurie Burdett, 2 Belynda Hicks, 2 Sarangan Ravichandran, 3 Brian T. Luke, 3 Meredith Yeager, 2 Laura Fontaine, 4 Paula L. Hyland, 1 Alisa M. Goldstein, 1 NCI DCEG Cancer Sequencing Working Group, NCI DCEG Cancer Genomics Research Laboratory, Stephen J. Chanock, 5 Neil E. Caporaso, 1 Margaret A. Tucker, 6 and Lynn R. Goldin 1 1Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 2Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 3Ad - vanced Biomedical Computing Center, Leidos Biomedical Research Inc.; Frederick National Laboratory for Cancer Research, Frederick, MD; 4Westat, Inc., Rockville MD; 5Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; and 6Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA ©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.135475 Received: August 19, 2015. Accepted: January 7, 2016. Pre-published: June 13, 2016. Correspondence: [email protected] Supplemental Author Information: NCI DCEG Cancer Sequencing Working Group: Mark H. Greene, Allan Hildesheim, Nan Hu, Maria Theresa Landi, Jennifer Loud, Phuong Mai, Lisa Mirabello, Lindsay Morton, Dilys Parry, Anand Pathak, Douglas R. Stewart, Philip R. Taylor, Geoffrey S. Tobias, Xiaohong R. Yang, Guoqin Yu NCI DCEG Cancer Genomics Research Laboratory: Salma Chowdhury, Michael Cullen, Casey Dagnall, Herbert Higson, Amy A.
  • Proteomic Expression Profile in Human Temporomandibular Joint

    Proteomic Expression Profile in Human Temporomandibular Joint

    diagnostics Article Proteomic Expression Profile in Human Temporomandibular Joint Dysfunction Andrea Duarte Doetzer 1,*, Roberto Hirochi Herai 1 , Marília Afonso Rabelo Buzalaf 2 and Paula Cristina Trevilatto 1 1 Graduate Program in Health Sciences, School of Medicine, Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba 80215-901, Brazil; [email protected] (R.H.H.); [email protected] (P.C.T.) 2 Department of Biological Sciences, Bauru School of Dentistry, University of São Paulo, Bauru 17012-901, Brazil; [email protected] * Correspondence: [email protected]; Tel.: +55-41-991-864-747 Abstract: Temporomandibular joint dysfunction (TMD) is a multifactorial condition that impairs human’s health and quality of life. Its etiology is still a challenge due to its complex development and the great number of different conditions it comprises. One of the most common forms of TMD is anterior disc displacement without reduction (DDWoR) and other TMDs with distinct origins are condylar hyperplasia (CH) and mandibular dislocation (MD). Thus, the aim of this study is to identify the protein expression profile of synovial fluid and the temporomandibular joint disc of patients diagnosed with DDWoR, CH and MD. Synovial fluid and a fraction of the temporomandibular joint disc were collected from nine patients diagnosed with DDWoR (n = 3), CH (n = 4) and MD (n = 2). Samples were subjected to label-free nLC-MS/MS for proteomic data extraction, and then bioinformatics analysis were conducted for protein identification and functional annotation. The three Citation: Doetzer, A.D.; Herai, R.H.; TMD conditions showed different protein expression profiles, and novel proteins were identified Buzalaf, M.A.R.; Trevilatto, P.C.
  • Human DOCK3 Antibody Antigen Affinity-Purified Polyclonal Sheep Igg Catalog Number: AF7134

    Human DOCK3 Antibody Antigen Affinity-Purified Polyclonal Sheep Igg Catalog Number: AF7134

    Human DOCK3 Antibody Antigen Affinity-purified Polyclonal Sheep IgG Catalog Number: AF7134 DESCRIPTION Species Reactivity Human Specificity Detects human DOCK3 in direct ELISAs. In direct ELISAs, less than 3% cross­reactivity with recombinant human (rh) DOCK1, rhDOCK2, and rhDOCK5 is observed. Source Polyclonal Sheep IgG Purification Antigen Affinity­purified Immunogen E. coli­derived recombinant human DOCK3 Gly418­Thr656 Accession # Q8IZD9 Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (­SP) is supplied either lyophilized or as a 0.2 μm filtered solution in PBS. APPLICATIONS Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website. Recommended Sample Concentration Immunohistochemistry 5­15 µg/mL See Below DATA Immunohistochemistry DOCK3 in Human Brain. DOCK3 was detected in immersion fixed paraffin­ embedded sections of human Alzheimer's brain (cortex) using Sheep Anti­Human DOCK3 Antigen Affinity­purified Polyclonal Antibody (Catalog # AF7134) at 3 µg/mL overnight at 4 °C. Tissue was stained using the Anti­Sheep HRP­DAB Cell & Tissue Staining Kit (brown; Catalog # CTS019) and counterstained with hemotoxylin (blue). Specific staining was localized to neurofibrillary tangles. View our protocol for Chromogenic IHC Staining of Paraffin­ embedded Tissue Sections. PREPARATION AND STORAGE Reconstitution Sterile PBS to a final concentration of 0.2 mg/mL. Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (­SP) is shipped with polar packs. Upon receipt, store it immediately at ­20 to ­70 °C Stability & Storage Use a manual defrost freezer and avoid repeated freeze­thaw cycles.